Description du projet
La phosphorylation dans les tumeurs plutôt que dans les tissus sains
L’ajout de phosphate aux protéines (phosphorylation) est un processus extrêmement important en biologie humaine pour la régulation de la fonction des protéines. Il sert de moyen de transmission à toutes sortes de signaux à l’intérieur des cellules et entre elles. Les kinases, les enzymes qui catalysent la phosphorylation, sont des cibles thérapeutiques pour un certain nombre de maladies importantes, notamment les cancers. Le projet TOPAS, financé par l’UE, prévoit d’améliorer le diagnostic et le traitement du cancer en cataloguant les protéines phosphorylées dans les tumeurs. Chercher comment les inhibiteurs de kinases modulent ce «phosphoprotéome» permettra de mieux comprendre les mécanismes d’action cellulaires des inhibiteurs anticancéreux de la kinase. Les applications permettront d’améliorer le développement de médicaments anticancéreux et les diagnostics.
Objectif
Kinases are key regulators of protein activity and phosphorylate thousands of proteins in cells. The phosphoproteome can hence be viewed as a proxy for the proteome activity status of a cell. Dysregulation of the phosphoproteome can cause diseases such as cancer. As a result, kinase inhibitors have become important drugs in oncology and nearly 50 are approved for use in humans. As they typically have a range of targets, there is enormous potential for repurposing these drugs for other cancer entities. To implement this in the clinic, it is important to better understand: i) how the phosphoproteome of an individual tumor can be functionally interpreted, ii) how and to what extent kinase inhibitors modulate the phosphoproteome and iii) which drug is the best fit for modulating the proteome activity status of a particular tumor. This information is only partially or not available from classical cancer diagnostics or genomics. Therefore, the central aim of this project is to show that ground breaking new information for the diagnosis and treatment of cancer patients will come from measuring their tumor proteome activity status (TOPAS) by quantitative mass spectrometry. To this end, the first objective is to show that modulating the TOPAS of cancer model systems by kinase inhibitors functionalizes the phosphoproteome and reveals the cellular mechanisms of action of these important medicines. The second objective is to develop and validate diagnostic drug-, protein- and pathway-centric TOPAS scores able to make treatment suggestions based on the phosphoproteomes of cancer models and tumor tissues. The third objective is to demonstrate, on the example of sarcoma patients, that TOPAS scoring adds value to decision making by molecular tumor boards. Combining the strengths of proteomics and genomics, I aim for building a comprehensive multi-omics view on tumors and will create a ‘virtual tumor board’ in ProteomicsDB to make TOPAS available to the scientific community.
Champ scientifique
Programme(s)
Thème(s)
Régime de financement
ERC-ADG - Advanced GrantInstitution d’accueil
80333 Muenchen
Allemagne